Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Selected Articles from This Issue

DOI:  Published January 2020
  • Article
  • Info & Metrics
  • PDF
Loading

Precision Chemo-radiotherapy Using MMAF Antibody Conjugates

Hingorani et al. Page 157

Although cytotoxic chemotherapies improve the control of locally advanced, non-metastatic tumors with radiotherapy, their lack of targeting can increase the damage done to nearby normal tissue and induce systemic toxicities. To achieve a more targeted radiosensitization, Hingorani and colleagues combined anti-HER2 antibody-drug conjugates bearing monomethyl auristatin E (MMAE) or auristatin F (MMAF) with radiotherap. to treat various HER2-expressing tumors. Despite the decreased permeability of MMAF-conjugated antibodies, their administration alongside radiotherapy significantly enhanced tumor control and improved mouse survival. Anti-HER2 MMAF conjugates also demonstrated decreased bystander accumulation and off-target effects compared to MMAE. Taken together, the results demonstrate cell impermeable radiosensitizing warheads represent a potent application of antibody-drug conjugates.

Multi-functional Targeting Improves Systemic Cancer Control

Zhang et al. Page 39

Organ destruction by metastatic cancer is a dominant clinical problem. Therapy directed at different functions that drive this process constitutes a rational approach to advance disease control. Zhang and colleagues demonstrate that combining inhibitors of cell motility with inhibitors of cell growth or with modulators of the bone microenvironment is highly efficacious across several clinically relevant models. Multifunctional therapy as a therapeutic strategy should be examined in humans. In the specific case of prostate cancer, combined inhibition of cell motility and modification of the bone microenvironment is highly efficacious.

Biomarkers of Response to Taselisib in Breast Cancer Models

Moore et al. Page 292

Mutations in the alpha subunit of PI3K (PIK3CA) are common in breast cancer and result in constitutive activation of the PI3K signaling pathway. Taselisib (GDC-0032) potently inhibits PI3K while reducing the on-target PI3K toxicities of its predecessors (e.g. pictilisib, buparlisib). To guide Taselisib's clinical development, Moore and colleagues use an unbiased approach to determine biomarkers of taselisib response in preclinical breast cancer models. They associate the role of PIK3CA mutations with PTEN, HER2, and estrogen receptor (ESR1) status in determining sensitivity to Taselisib. Their results suggest that Taselisib use should occur in PIK3CA mutant settings and that combined therap. should be guided by the subtype.

Biomarkers for CDK4/6 Inhibitors

Schoninger and Blain Page 3

CDK4 and CDK6 regulate the G1/S phase transition and serves as a downstream effector of many oncogenic signaling pathways. Therefore, a great deal of effort has been placed in inhibiting these critical regulators, and the FDA approval of Palbociclib, Abemaciclib and Ribociclib demonstrates this success. However, treatment with CDK4/6 inhibitors is challenged by primary or secondary resistance, highlighting a need for biomarkers that will identify the patients who would derive the most benefit. This review by Schoninger and Blain provides a roadmap for the development of potential CDK4i biomarkers, informed by the biological basis of CDK4/6 signaling and recent clinical support.

  • ©2020 American Association for Cancer Research.
Next
Back to top
Molecular Cancer Therapeutics: 19 (1)
January 2020
Volume 19, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Selected Articles from This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Selected Articles from This Issue
Mol Cancer Ther January 1 2020 (19) (1) 1;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Selected Articles from This Issue
Mol Cancer Ther January 1 2020 (19) (1) 1;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Precision Chemo-radiotherapy Using MMAF Antibody Conjugates
    • Multi-functional Targeting Improves Systemic Cancer Control
    • Biomarkers of Response to Taselisib in Breast Cancer Models
    • Biomarkers for CDK4/6 Inhibitors
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement